Hillstream BioPharma Provides Webcast for its R&D Day on February 14th, 2023 at 10:00am ET
February 13 2023 - 4:15PM
Hillstream BioPharma, Inc. (Nasdaq: HILS) ("Hillstream" or the
"Company"), a biotechnology company developing therapeutic
candidates targeting drug resistant and devastating cancers using
ferroptosis, an emerging new anti-cancer mechanism resulting in
iron mediated cell death, and immuno-oncology targeted novel
biologics, is providing webcast access to their virtual R&D
Day, being held on Tuesday, February 14, 2023.
Webcasting Information
Event: |
Hillstream Virtual R&D Day |
Date: |
Tuesday, February 14, 2023 |
Time: |
10:00 a.m. Eastern Time |
Live Call: |
1-877-405-1216 (U.S. Toll-Free)
or 1-201-689-8336 (International) |
Webcast: |
https://event.webcasts.com/starthere.jsp?ei=1598049&tp_key=ea78bcc6d0 |
The Company invites and encourages its shareholders and
prospective investors to watch its R&D Day webcast. A replay of
the R&D Day can be accessed via Hillstream’s IR site, or
by dialing 1-877-660-6853 / 201-612-7415 and entering pin number
13736356.
Following prepared remarks, the Company’s guest speakers will
discuss Hillstream’s R&D strategy, upcoming presentations,
emerging pipeline assets, and anticipated milestones:
- Randy Milby: Chief Executive
Officer, Hillstream
- Donald Kufe, MD: Distinguished
Physician at the Dana-Farber Cancer Institute, Professor of
Medicine at Harvard Medical School and Chair, Hillstream’s
Scientific Advisory Board
- Vaughn Smider, MD, Ph.D.: Chief
Executive Officer, Applied Biomedical Science Institute
Hillstream is addressing some of the biggest problems in cancer
today including drug resistance and cancer metastasis. The Company
is attempting to transform the treatment of drug resistant cancers
with ferroptosis, an emerging new anti-cancer mechanism which leads
to iron mediated cell death. The Company focuses on key target
oncology markets which include small cell lung cancer (SCLC),
triple negative breast cancer (TNBC), and metastatic castration
resistant prostate cancer (mCRPC), projected to reach $11 billion
by 2028.
The Company recently announced preclinical results which
demonstrated significantly greater tumor inhibition when combining
its most advanced drug candidate HSB-1216 with immune checkpoint
inhibitors in KRAS G12C-mutated non-small cell lung cancer (NSCLC)
cells, Calu-1, with pembrolizumab (KEYTRUDA®) an anti-PD-1
antibody.
Additionally, yesterday, Hillstream signed an exclusive option
agreement with Applied Biomedical Science Institute to license
technology for HER2 and HER3 Conformational Domain Bridging
Epitopes in human monoclonal antibodies to develop proprietary
multi-format biologics (bi- and tri-specific antibodies, ADCs
(antibody drug conjugates), CAR-T and CAR-NKs, in Quatramers and
Quatrabodies) against drug resistant cancers including
HER2-positive metastatic breast cancer, gastric cancer, lung cancer
and ovarian cancer.
About Hillstream BioPharma Inc.Hillstream
BioPharma, Inc. is a biotechnology company developing therapeutic
candidates targeting drug resistant and devastating cancers using
ferroptosis, an emerging new anti-cancer mechanism resulting in
iron mediated cell death, and immuno-oncology targeted novel
biologics. The Company’s most advanced candidate, HSB-1216,
expected to enter clinical trials in 2023, targets ferroptosis, an
emerging new anti-cancer mechanism resulting in iron mediated cell
death (IMCD) of drug resistant cancers. The Company’s emerging
immuno-oncology pipeline is led by the HSB-1940 Quatrabody™, an
anti-PD-1 novel biologic coated onto Quatramers, expected to enter
the clinic in 2024. Hillstream’s Quatramer™ proprietary tumor
targeting platform extends duration of action and minimizes
off-target toxicity for biologics, mRNA, peptides, small molecules
and other modalities in the tumor microenvironment. Quatrabody
conjugates novel biologics developed against undruggable epitopes
of validated immuno-oncology targets, including PD-1, HER2, PDL-1
and TROP2 with greater binding affinity than approved therapies.
For more information, please visit: www.hillstreambio.com.
Forward Looking StatementsCertain statements in
this press release are forward-looking within the meaning of the
Private Securities Litigation Reform Act of 1995. These statements
may be identified using words such as “anticipate,” “believe,”
“forecast,” “estimated” and “intend” or other similar terms or
expressions that concern Hillstream’s expectations, strategy, plans
or intentions. These forward-looking statements are based on
Hillstream’s current expectations and actual results could differ
materially. There are several factors that could cause actual
events to differ materially from those indicated by such
forward-looking statements. These factors include, but are not
limited to, clinical trials involve a lengthy and expensive process
with an uncertain outcome, and results of earlier studies and
trials may not be predictive of future trial results; our clinical
trials may be suspended or discontinued due to unexpected side
effects or other safety risks that could preclude approval of our
product candidates; risks related to business interruptions,
including the outbreak of COVID-19 coronavirus, which could
seriously harm our financial condition and increase our costs and
expenses; dependence on key personnel; substantial competition;
uncertainties of patent protection and litigation; dependence upon
third parties; and risks related to failure to obtain FDA
clearances or approvals and noncompliance with FDA regulations.
Investors should read the risk factors set forth in our Form 10-K
for the year ended December 31, 2021 and our periodic reports filed
with the Securities and Exchange Commission. While the list of
factors presented here is considered representative, no such list
should be considered to be a complete statement of all potential
risks and uncertainties. Unlisted factors may present significant
additional obstacles to the realization of forward-looking
statements. Forward-looking statements included herein are made as
of the date hereof, and Hillstream does not undertake any
obligation to update publicly such statements to reflect subsequent
events or circumstances.
Investor Relations
Contact:Email: investorrelations@hillstreambio.comwww.hillstreambio.com
Hillstream BioPharma (NASDAQ:HILS)
Historical Stock Chart
From Mar 2024 to Apr 2024
Hillstream BioPharma (NASDAQ:HILS)
Historical Stock Chart
From Apr 2023 to Apr 2024